Insilico Medicine
Hong Kong · Founded 2019 · 291 employees on LinkedIn · 16 known investors
Find your way into Insilico Medicine
221 people in our graph share verified history with the Insilico Medicine team — schools, employers, funds. One of them is your warm intro.
Eugene Chernyavskyunlockedknows Alex Zhavoronkov · together at Moscow Institute of Physics and Technology (State University) - MIPT, Phystech (overlapped)
×8knows the team · via Lomonosov Moscow State University (MSU)
knows the team · via PMC-Sierra, Inc
×2knows the team · via ATI Technologies, Inc, Markham, Canada
Insilico Medicine uses artificial intelligence to discover and develop new drugs, operating an AI-driven platform for pharmaceutical research and development. It collaborates with global biopharma companies and academic institutions on drug discovery projects.
Founders & leadership
Insilico Medicine was founded in 2019 by Alex Zavoronkov, Alex Zhavoronkov, and Alex Aliper.
AZ
Alex ZavoronkovCo-founder
AZ
Alex ZhavoronkovinFounder & CEOAlex Zhavoronkov founded Insilico Medicine in 2014, an AI-driven drug discovery company focused on developing generative chemistry and biology platforms for pharmaceutical research; the company has advanced multiple candidates through clinical trials in immunology, oncology, fibrosis, and aging-related diseases.
AA
Alex AliperinPresident
FR
Feng ReninChief Scientific Officer, Executive Director & Co-CEO
Board
NL
Nisa LeungBoard director
LL
Lennart LeeBoard director
JM
James MellonBoard director
Investors · 16
Lilly Asia Ventures✓ verifiedHong Kongvia Hongbo Lu · inferred
OrbiMed✓ verifiedNew York · $1M – $75M
Qiming Venture Partners✓ verifiedBeijing · $5M – $134M
Warburg Pincus✓ verifiedNew York
Baidu Ventures✓ verifiedBeijing · $1.4M – $145M
Eight Roads Ventures✓ verifiedMumbai · $5M – $30M
Lake Bleu Capital✓ verifiedHong Kong
Sinovation Ventures✓ verifiedBeijing · $1M – $110M
.jpeg){kind=logo}
B Capital GroupManhattan Beach · $10M – $50M
B4 Capital$10M – $50M
BOLD LongevityBoston
F-Prime CapitalCambridge · $3M – $10M
Gestio CapitalLondon
LAVHong Kong · $5M – $15M
LongeVCWashington D.C.
Prosperity7 VenturesDhahran
Reported raises · per SEC filings
Form D private placements$36.8M disclosed across 1 round · 2019
▶$36.8MraisedSep 2019 · 21 investors · BiotechnologyRule 506(b)
▶$36.8MraisedSep 2019 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- [none] WNL LimitedDirector
- Nisa LeungDirector
- Lennart LeeDirector
- Alex ZavoronkovDirector
- James MellonDirector
- Offering amount
- $36.8M
- Amount sold
- $36.8M
- First sale
- Sep 2019
- Incorporated
- Other, Cayman Islands, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Insilico Medicine Included in MSCI Global Small Cap Indexes, Gaining Capital Market Endorsement in Core Strengths | The Manila Timesmanilatimes.net · Aug 2026Frequently asked questions
- What does Insilico Medicine do?
- Insilico Medicine uses artificial intelligence to discover and develop new drugs, operating an AI-driven platform for pharmaceutical research and development. It collaborates with global biopharma companies and academic institutions on drug discovery projects.
- Who founded Insilico Medicine?
- Insilico Medicine was founded by Alex Zavoronkov, Alex Zhavoronkov, Alex Aliper in 2019.
- Who are Insilico Medicine's investors?
- Insilico Medicine's investors include Lilly Asia Ventures, OrbiMed, Qiming Venture Partners, Warburg Pincus, Baidu Ventures, Eight Roads Ventures, Lake Bleu Capital, Sinovation Ventures and 8 more.
- How much funding has Insilico Medicine raised?
- Insilico Medicine has disclosed $36.8M raised across 1 round.
- Where is Insilico Medicine headquartered?
- Insilico Medicine is headquartered in Hong Kong.